Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
2023-08-17 08:45:00
New Operating Model
- In Q2 2023 QLife has completed restructuring of its operation by reducing the number of employees and terminating a long term lease for production facilities. With these activities behind us QLife is ready for the future with a new lean partner based operating model.
- Revenue in the period amounted to kSEK 46 (4,025). Revenue includes sales of Egoo.Health devices and capsules for the device. As the company has discontinued the COVID test capsules revenue is from the first test orders of CRP capsules and Egoo systems.
- EBITDA for the period amounted to kSEK -16,287 (-20,623), and net loss kSEK -24,869 (-23,781).
- The total cash flow in the first quarter amounted to kSEK 7,894 (-8,977).
- Earnings per share before/after dilution for the second quarter amounted to SEK -0.05 (-1.30), calculated on weighted average number of shares in the period.
- Revenue in the period amounted to kSEK 169 (14,930). Revenue includes sales of Egoo.Health devices and capsules for the device.
- EBITDA for the period amounted to kSEK -27,860 (-36,918), and net loss kSEK -39,484 (-35,419).
- The total cash flow in the first half amounted to kSEK -4,217 (-39,713).
- Earnings per share before/after dilution for the first half of 2023 amounted toSEK -0.16 (-2.29), calculated on weighted average number of shares in the period.
- Qlife Holding announces the outcome of the exercise of warrants series TO 2
- Qlife publishes outcome of rights issue
On April 27th Qlife announced the outcome the the rights issue that was announced in February 2023. The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unitrights. In addition, 56,332,035 units were subscribed for without unit rights, corresponding to approximately 9.8 percent of the Rights Issue, and underwriters subscribed for 397,627,615 units, corresponding to approximately 68.9 percent of the Rights Issue. Accordingly, the Rights Issue has been subscribed for to a total of 100 percent. The Company will thus receive total proceeds of approximately SEK 57.7 million before transaction costs, and upon full exercise of all warrants, Qlife will receive additional proceeds of a maximum of approximately SEK 67 million before transaction costs. Due to the completion of Rights Issue, a recalculation of the exercise terms for the Company's previously issued warrants series TO 2 has been carried out and has resulted in that the highest subscription price in the interval now amounts to SEK 9.27 and that each warrant series TO 2 entitles the right to subscribe for 1.08 new share in the Company. The other terms and conditions for warrants series TO 2 remain unchanged.
- Launch of Egoo Health and CRP test
- Announcement of rights issue
- Launch of Egoo Innovate
CA Qlife made the official launch of Egoo Innovate, offering Egoo as an open system for researchers to implement their biomarker assays and bring them into at-home or pointof-need surroundings.Significant events after the end of 1st half 2023
- Directed issue of convertibles
On August 3rd the board of directors of Qlife Holding AB ("Qlife" or the "Company") has, pursuant to the authorization granted by the annual general meeting on 4 May 2023, resolved on a directed issue of a convertible loan raising gross proceeds of SEK 4,647,035prior to deduction of transaction costs. The convertible loan is expected to satisfy the Company's financing need until the end of 2023.
Link to Q2 report on Qlife Holdings webpage (https://qlifeholding.com/sites/default/files/2023-08/Qlife_Q2_2023.pdf).